Small Molecule API Market
Small Molecule API to be most extensively deployed for Oncological Research
Small Molecule API Market By Molecule Type, Production, Application, Therapeutic Area, Region - Forecast 2022-2032
Small Molecule API Market Overview (2022-2032)
[300 Pages Report] Global demand for Small Molecule API is expected to rise at a yearly growth rate of 5.0% Y-o-Y to US$ 216.97 Billion in 2032, supported by:
- Key advancements in drug development technologies and increasing clinical trials to the fuel growth rate.
- Increasing emergence of specialty medicines lead to a paradigm shift in the industry.
- Stringent FDA regulations & policies to hinder the approval of new drugs
- Oncology segment to dominate, propelled by the increasing diagnosis of cancer
During the period ranging from 2020 to 2022, the demand prospects for Small Molecule API proliferated, backed by the increasing diagnosis of chronic diseases. Increasing research on small molecule APIs will boost the Small Molecule API Market growth. As per this report, demand for Small Molecule API for automotive production is expected to surge at over 5% CAGR until 2032.
Small-molecule pharmaceuticals accounted for 82% of all new drug application (NDA) approvals in 2021 and 60% of all new molecular entities. Further, they represent two-thirds of the drug-development pipeline.
Undoubtedly, the number and share of large-molecule therapeutics are increasing, small-molecule drugs are a crucial and highly effective component of the bio/pharmaceutical portfolio. Many of the most important drugs introduced in the past, including kinase inhibitors such as Gleevec and anti-retroviral products such as Sovaldi, are small molecules.
|
Report Attribute |
Details |
|
Small Molecule API Market Estimated Base Year Value (2021) |
US$ 170 Billion |
|
Expected Market Value (2022) |
US$ 178.5 Billion |
|
Anticipated Forecast Value (2032) |
US$ 290.76 Billion |
|
Projected Growth Rate (2022-2032) |
5% CAGR |
Let us know your requirement to get
100% FREE customization
Mushrooming Healthcare Industry To Provide A Strong Base For Small Molecule API Manufacturers In The Asia Pacific
In terms of regional growth, Asia Pacific is estimated to capture a significant market share, expanding at 5.5% CAGR in 2022. This market growth is attributed to the rapid-paced expansion of API units and the growing prevalence of chronic illnesses. Within the Asia Pacific, China is expected to offer numerous growth prospects for the small molecule API market, closely followed by India with the fastest growth rate.
In March 2022, Lonza announced the completion of the expansion of its laboratory in China’s API manufacturing facility, which allows the company to focus on small molecule high potency APIs.
India is set to witness a growth rate equivalent to 5% concerning growing investment in new drug development. After the unprecedented occurrence of SARS covid-19 in recent years, drug manufacturers have learned to prep themselves for future instances. Consequently, Small Molecule API manufacturers are seizing this opportunity to make inroads in the regional market.
Opportunities Abound In The Therapeutic Area Segment
With the rising number of new entrants in the market, the demand prospects for small molecules API are likely to upsurge. For instance, as per NCBI in 2021, 75% of the drugs accepted by the FDA were small molecules, with the dominant therapeutic area being oncology accounting for 26% share.
More than 50% of these sanctions were from small and mid-sized companies which require funding from CDMOs for the commercialization of products that boost the growth rate of CDMOs.
Small molecule API plays an imperative role in drug development for curing cancer. According to the World Health Organization (WHO), cancer is the second-leading cause of death around the world. With the prevalence forecast to rise further, the demand for small molecule API will surge in the coming years. Thereby, prominent players in the healthcare industry are constantly investing in R&D for the development of new drugs to treat chronic diseases.
Small molecules are chemical substances composed of two or more atoms with a molecular weight of less than 900 Dalton. Socioeconomic concerns and health issues in terms of the prevalence of chronic diseases are prioritized around the world. This has resulted in the improvement in production facilities within the pharmaceutical sector, which has been fuelling the demand for active pharmaceutical ingredients (API).
While biologics are gradually making their presence felt, Small Molecule API continues to be the cornerstone of pharmaceutical development. The rise in demand for effective treatment for chronic disease in various therapeutic areas has been fuelling the demand for small molecule API market.
Find your sweet spots for generating winning opportunities in this market.
Talk to Analyst2017-2021 Small Molecule API Market Analysis vs. Forecast 2022-2032
The global demand for Small Molecule API market is projected to increase at a CAGR of 5% during the forecast period between 2022 and 2032, reaching a total of US$ 290.76 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 4.5%.
In-House and outsourcing manufacturing of small molecule API continue to be hot topics in the pharmaceutical sector. The demand for outsourcing manufacturing in the small molecule API market has been on the rise because of increasing production costs and burden management. Subsequently, rising incidence of chronic diseases, besides investment in research and development (R&D) initiatives have been enabling growth.
Factors such as the availability of several promising drug pipelines that have disease-modifying properties and a better safety and efficacy profile are attracting an increasing number of players to the market.
Current suboptimal growth of contract development and manufacturing organizations (CDMOs), advancements in small molecule (API) manufacturing, an increasing number of abbreviated new drug applications (ANDA), growth of the healthcare market in the Asia Pacific and other developing countries, expansion in terms of product offering, and reduction in operational cost are creating opportunities for growth in small molecule API market.
Increasing diagnosis of chronic diseases has bolstered the production of small molecule API. Increasing research on small molecule APIs will boost the Small Molecule API Market growth. Driven by the above factors the market is expected to exhibit a CAGR of 5% through 2032.
An increase in government funding and policies favouring the entry of startups in the last two quarters of the year is creating growth opportunities. There is rapid development in the technologies that are used for the long-term delivery of medications in molecule type. Spurred by this, the Small Molecule API Market will continue exhibiting steady growth through the forecast period.
Which are Some Prominent Drivers of the Small Molecule API Market?
Rising Incidence of Chronic Ailments affecting Demand for Small Molecule API Market
API manufacturing has proven to be quite effective in the last few years. Besides this, factors such as increasing incidence of cancer and subsequently rising demand for effective diagnosis and R&D in oncology therapeutic will fuel the demand for small molecule oncology therapy. Small molecule oncology drugs have proven effective in cancer treatment.
While biologics are making their presence felt in the pharmaceutical sector, small molecule API will continue accounting for the majority of new drug applications. It also constitutes a significant share of the drug development pipeline. As of October 2021, 58% of molecules in the drug development process are small molecules.
This demonstrates a huge opportunity for contract manufacturers in the market. The core advantage of small molecules in delivering strong therapeutic benefits in smaller doses will remain a chief growth driver.
Increased Use of Novel Technologies Escalating Sales of Small Molecule API
Over the years, increased use of novel technologies and the emergence of speciality medicines have been leading to a paradigm shift in the industry. Furthermore, smaller volumes of production are projected to witness a surge. The increasing production of the number of products being launched is a result of flexible manufacturing units and robust processes developed to meet the demand.
The complexity of manufacturing is evolving towards increasingly complex molecules, thus creating the requirement for more compound manufacturing facilities. This is also in line with a pipeline that holds 30% of highly potent active pharmaceutical ingredients (HPAPI) along with the surge in demand for highly potent molecules.
A unified Market Research Subscription Platform, built for today's disparate research needs.
What are the Challenges Faced by the Small Molecule API Market?
Low Awareness Levels of Small Molecule APIs Hindering Growth
Even though there are many factors leading to the growth of small molecule APIs, there is still very low awareness regarding the same. This is especially true in case of underdeveloped countries and their poor economic standards. Also, healthcare infrastructure in these nations along with budgetary constraints could challenge the worldwide small molecule API market in the long run.
Small Molecule API Market - Region-Wise Insights
How are Small Molecule API Sales Faring in China?
Prevalence of Various Illnesses to Open Growth Opportunities
FMI has projected China to remain one of the most lucrative small molecule API markets. It is expected to register a CAGR of 5.5% during the forecast period. Besides increasing the incidence of various illnesses, the China market is driven by the expansion of API manufacturing units.
In March 2022, Lonza announced the completion of the expansion of its laboratory in China’s API manufacturing facility, which allows the company to focus on small molecule high potency APIs.
The presence of less stringent policies in terms of waste product management will continue to support growth in China. Besides this, social determination and growing R&D facilities in the country will enhance the Small Molecule API Market growth. In addition, increasing focus on patient awareness and the presence of major players have catapulted China to the forefront of small molecule API manufacturing.
What are the Prospects of Small Molecule API Production in Japan?
Consumers Spending on Medical Care to Push Growth Prospects
The per capita spending on medical care is increasing in Japan. Individuals' longing and capacity to spend on wellbeing has prompted a steady move in medical services consumption. In the course of the last few years, the worldwide per capita medical care spending has practically multiplied. As per FMI’s analysis, the Japanese small molecule API market is slated to register a CAGR worth 5.4% from 2022 to 2032.
Fast financial and populace development just as expanding extra cash is the superb component answerable for the development of the general medical care industry. This has also helped in the expansion of the Small Molecule API Market in Japan. The presence of some of the leading players also has been supporting growth.
What is Driving Small Molecule API Development in India?
Increased Pharmaceutical Manufacturing to Propel Growth
As per the India Brand Equity Foundation (IBEF), the Indian pharmaceutical trade reached US$ 16.2 Trillion by 2020. Pharma Vision 2020 will advance the pioneer in start to finish assembling of API. 100% FDI has been permitted for the programmed course for the creation of API.
India holds a lucrative production globally in terms of pharmaceutical manufacturing. The nation likewise has an enormous pool of researchers and architects with the possibility to guide the business ahead to a more prominent status. By and by, more than 80% of the antiretroviral drugs utilized universally to battle Acquired Immune Deficiency Syndrome (AIDS) are provided by Indian drug firms.
Coupled with this, the World Health Organization (WHO) reported the setting up of the Global Center of Traditional Medicine in India. These factors are spurring pharmaceutical production in India, in turn fuelling the demand for small molecule API.
What is the Small Molecule API Market Outlook in Germany?
Rising Onychomycosis Cases Elevating Small Molecule API Demand in Germany
Germany will continue to dominate the small Molecule API market in Europe. It is expected to contribute over 30% of sales in the Europe market. The rising incidence of various ailments, together with increasing pharmaceutical spending has been fuelling demand in the country. With prevailing trends indicating increasing spending, the investment in small API molecules is expected to increase.
Small Molecule API Market - Category-Insights
Which is the Leading Small Molecule API Type?
The Standard API will continue to hold maximum share in the global small molecule API market with a market share of over 79.6%. The growth is attributable to its dominance in the pharmaceutical industry that propels the demand for raw materials such as small molecule APIs for production. Furthermore, the ease of production of these molecules and high effectiveness boost the segment growth.
The presence of many players in the synthetic segment is accelerating its growth. Moreover, an increasing number of players are aiming at backward integration and building new manufacturing plants to increase efficiency.
Which is the Key Therapeutic Area for Small Molecule API?
Oncology accounts for 26.6% of the Small Molecule API Market share by therapeutic area. Small molecule API plays a crucial role in drug development for the treatment of cancer. According to the World Health Organization (WHO), cancer is the second-leading cause of death around the world. With the incidence forecast to rise further, the demand for small molecule API will surge in the coming years.
However, the introduction of combination drugs and increment in R&D in drug development for the molecule type of oncology therapeutic area is expected to result in reduced sales of oncology drug induced Small Molecule API.
Why Does Commercial Application Account for Greater Sales of Small Molecule API?
According to FMI, the demand for small molecule API will be highest in commercial use. The commercial segment will lead throughout the forecast period. The rising use of API in pharmaceutical manufacturing will continue enabling sales in the segment.
The Start-Up Ecosystem: How Key Players are Opening Frontiers for Future Growth?
Some of the startups in the small molecule API market include Exscientia, ATAI, Schrodinger, Benevolent, HotSpot Therapeutics, Insitro, Atomwise, AbCellera, Certara, and Oxford Drug Design. Some of the key developments include-
- In March 2022, Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs. The Xcellomics program was created by the two Oxford-based institutions to expedite early-stage drug discovery research – primarily conducted within academic labs – and potentially leverage those outputs to bring therapies to patients sooner. The program offers applicants resources to explore, identify and rapidly advance novel drug targets by leveraging Oxford TDI’s expertise in developing robust, disease-relevant, predictive screening assays and Exscientia’s AI personalized medicine design capabilities.
- In June 2022, Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that the U.S. Food and Drug Administration(FDA) cleared its investigational new drug (IND) application for its MALT1 inhibitor, SGR-1505. Schrödinger expects to initiate a Phase 1 clinical trial of SGR-1505 in patients with relapsed or refractory B-cell lymphoma in the second half of 2022.
Small Molecule API Market Competition
Key players in the Small Molecule API market are Pfizer Inc., Johnson Matthey, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., Sanofi S.A., Novartis AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, GILEAD Science Inc., Albany Molecular Research Inc., AstraZeneca, Merck & Co, Inc., BASF SE, Teva Pharmaceuticals, and Hoffmann-La Roche Ltd.
- In March 2021, U.S. Food and Drug Administration (FDA) has accepted New Drug Application for Gefapixant, an orally administered for the Molecule Type of refractory chronic cough (RCC) in adults.
- In March 2022, Sumitomo Chemical Co., Ltd. announced its investment to build a new manufacturing facility in Japan to meet the surge in demand for high-quality small molecule APIs and intermediates.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2022 |
US$ 178.5 Billion |
|
Market Value in 2032 |
US$ 290.76 Billion |
|
Growth Rate |
CAGR of 5% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2017-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
Key Segments Profiled in the Small Molecule API Market Industry Survey
By Molecule Type:
- Standard API
- HPAPI
By Production:
- Captive/In-House
- Outsourced
By Application:
- Clinical
- Commercial
By Therapeutic Area:
- Cardiovascular Diseases
- Respiratory Disorders
- Infectious Diseases
- Metabolic Disorders
- Oncology
- Immunology
- Neurology
- Urology
- Dermatology
- Ophthalmology
- General Health
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
What is the anticipated growth of the market Small Molecule API until 2032?
FMI projects the global Small Molecule API market to expand at a 5% value CAGR by 2032
What is the estimated market value of the Small Molecule API market expected in 2022?
The global Small Molecule API market is estimated at a market value of US$ 178.5 Billion
What is the estimated market value of the Small Molecule API market expected in 2032?
The global Small Molecule API market is expected to garner a market value of US$ 290.76 Billion
Which region is forecast to be the most lucrative for Small Molecule API market growth?
FMI has projected China to remain one of the most lucrative markets for small molecule API, registering a CAGR of over 5.5% during the forecast period.
Which are some prominent Small Molecule API manufacturers?
Pfizer Inc., Johnson Matthey, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., Sanofi S.A., Novartis AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, GILEAD Science Inc., Albany Molecular Research Inc., AstraZeneca, Merck & Co, Inc., BASF SE, Teva Pharmaceuticals, and Hoffmann-La Roche Ltd. are some prominent Small Molecule API manufacturers.
What is the expected market share of Germany for Small Molecule API in the forecast period 2022-2032?
Germany is expected to contribute over 30% of sales in the European market for Small Molecule API market in the forecast period 2022-2032.
Which type of small molecule API is expected to hold the largest market share for Small Molecule API in the forecast period 2022-2032?
The Standard API will continue to hold maximum share in the global small molecule API market with a market share of over 79.6%.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Drug Development Trends 4. Key Success Factors 4.1. API Drug Manufacturing / Usage Analysis 4.2. New API Drug Launches and Regulatory Approvals 4.3. Key Strategies Followed By Manufacturers 4.4. Regulatory Scenario 4.5. Key Promotional Strategies, By Manufacturers 5. Market Demand (Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032 5.1. Historical Market Value (US$ Mn) Analysis, 2017-2021 5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Market Background 6.1. Macro-Economic Factors 6.1.1. Global GDP Growth Outlook 6.1.2. Per Capita Healthcare Expenditure Outlook 6.2. Forecast Factors - Relevance & Impact 6.2.1. API Drug Adoption Rate and Demand 6.2.2. New API Molecule Type Approvals and Launches 6.2.3. Rising R & D Funding 6.2.4. Increasing Application of API or Small Molecule Types 6.2.5. Regulatory Policies 6.2.6. Treatment Seeking Rate 6.3. Market Dynamics 6.3.1. Drivers 6.3.2. Restraints 6.3.3. Opportunity Analysis 6.4. COVID19 Crisis Analysis 6.4.1. Current COVID19 Statistics and Probable Future Impact 6.4.2. Current GDP Projection and Probable Impact 6.4.3. COVID19 and Impact Analysis 6.4.3.1. Revenue By Molecule Type 6.4.3.2. Revenue By Production 6.4.3.3. Revenue By Application 6.4.3.4. Revenue By Therapeutic Area 6.4.3.5. Revenue By Country 6.4.4. 2022 Market Scenario 6.4.5. Quarter by Quarter Forecast 6.4.6. Projected recovery Quarter 7. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Molecule Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) By Molecule Type, 2017-2021 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Molecule Type, 2022-2032 7.3.1. Standard API 7.3.2. HPAPI 7.4. Market Attractiveness Analysis By Molecule Type 8. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Production 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) By Production, 2017-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Production, 2022-2032 8.3.1. Captive/In-House 8.3.2. Out Source 8.4. Market Attractiveness Analysis By Production 9. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2017-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2032 9.3.1. Clinical 9.3.2. Commercial 9.4. Market Attractiveness Analysis By Application 10. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Therapeutic Area 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2017-2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2022-2032 10.3.1. Cardiovascular Diseases 10.3.2. Respiratory Disorders 10.3.3. Infectious Diseases 10.3.4. Metabolic Disorders 10.3.5. Oncology 10.3.6. Immunology 10.3.7. Neurology 10.3.8. Urology 10.3.9. Dermatology 10.3.10. Ophthalmology 10.3.11. General Health 10.3.12. Others 10.4. Market Attractiveness Analysis By Therapeutic Area 11. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2029 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2017-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Molecule Type 12.3.3. By Production 12.3.4. By Application 12.3.5. By Therapeutic Area 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Latin America Market Analysis 2017-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014 - 2018 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Molecule Type 13.3.3. By Production 13.3.4. By Application 13.3.5. By Therapeutic Area 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Europe Market Analysis 2017-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy2022-2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Molecule Type 14.3.3. By Production 14.3.4. By Application 14.3.5. By Therapeutic Area 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. South Asia Market Analysis 2017-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy2022-2032 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Molecule Type 15.3.3. By Production 15.3.4. By Application 15.3.5. By Therapeutic Area 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. East Asia Market Analysis 2017-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Molecule Type 16.3.3. By Production 16.3.4. By Application 16.3.5. By Therapeutic Area 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Oceania Market Analysis 2017-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Molecule Type 17.3.3. By Production 17.3.4. By Application 17.3.5. By Therapeutic Area 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Market Analysis 2017-2021 and Forecast 2022-2032 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. Rest of Middle East and Africa 18.3.2. By Molecule Type 18.3.3. By Production 18.3.4. By Application 18.3.5. By Therapeutic Area 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Key and Emerging Countries Market Analysis 2017-2021 and Forecast 2022-2032 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Market Analysis 19.2.1. By Molecule Type 19.2.2. By Production 19.2.3. By Application 19.2.4. By Therapeutic Area 19.3. Canada Market Analysis 19.3.1. By Molecule Type 19.3.2. By Production 19.3.3. By Application 19.3.4. By Therapeutic Area 19.4. Mexico Market Analysis 19.4.1. By Molecule Type 19.4.2. By Production 19.4.3. By Application 19.4.4. By Therapeutic Area 19.5. Brazil Market Analysis 19.5.1. By Molecule Type 19.5.2. By Production 19.5.3. By Application 19.5.4. By Therapeutic Area 19.6. U.K. Market Analysis 19.6.1. By Molecule Type 19.6.2. By Production 19.6.3. By Application 19.6.4. By Therapeutic Area 19.7. Germany Market Analysis 19.7.1. By Molecule Type 19.7.2. By Production 19.7.3. By Application 19.7.4. By Therapeutic Area 19.8. France Market Analysis 19.8.1. By Molecule Type 19.8.2. By Production 19.8.3. By Application 19.8.4. By Therapeutic Area 19.9. Italy Market Analysis 19.9.1. By Molecule Type 19.9.2. By Production 19.9.3. By Application 19.9.4. By Therapeutic Area 19.10. Spain Market Analysis 19.10.1. By Molecule Type 19.10.2. By Production 19.10.3. By Application 19.10.4. By Therapeutic Area 19.11. BENELUX Market Analysis 19.11.1. By Molecule Type 19.11.2. By Production 19.11.3. By Application 19.11.4. By Therapeutic Area 19.12. Russia Market Analysis 19.12.1. By Molecule Type 19.12.2. By Production 19.12.3. By Application 19.12.4. By Therapeutic Area 19.13. China Market Analysis 19.13.1. By Molecule Type 19.13.2. By Production 19.13.3. By Application 19.13.4. By Therapeutic Area 19.14. Japan Market Analysis 19.14.1. By Molecule Type 19.14.2. By Production 19.14.3. By Application 19.14.4. By Therapeutic Area 19.15. South Korea Market Analysis 19.15.1. By Molecule Type 19.15.2. By Production 19.15.3. By Application 19.15.4. By Therapeutic Area 19.16. India Market Analysis 19.16.1. By Molecule Type 19.16.2. By Production 19.16.3. By Application 19.16.4. By Therapeutic Area 19.17. ASEAN Market Analysis 19.17.1. By Molecule Type 19.17.2. By Production 19.17.3. By Application 19.17.4. By Therapeutic Area 19.18. Australia Market Analysis 19.18.1. By Molecule Type 19.18.2. By Production 19.18.3. By Application 19.18.4. By Therapeutic Area 19.19. New Zealand Market Analysis 19.19.1. By Molecule Type 19.19.2. By Production 19.19.3. By Application 19.19.4. By Therapeutic Area 19.20. GCC Countries Market Analysis 19.20.1. By Molecule Type 19.20.2. By Production 19.20.3. By Application 19.20.4. By Therapeutic Area 19.21. Turkey Market Analysis 19.21.1. By Molecule Type 19.21.2. By Production 19.21.3. By Application 19.21.4. By Therapeutic Area 19.22. South Africa Market Analysis 19.22.1. By Molecule Type 19.22.2. By Production 19.22.3. By Application 19.22.4. By Therapeutic Area 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. By Regional footprint of Players 20.4.2. Product foot print by Players 20.4.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Johnson Matthey 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.1.5.1. Marketing Strategy 21.3.1.5.2. Product Strategy 21.3.1.5.3. Channel Strategy 21.3.2. Pfizer Inc. 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.2.5.1. Marketing Strategy 21.3.2.5.2. Product Strategy 21.3.2.5.3. Channel Strategy 21.3.3. Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.3.5.1. Marketing Strategy 21.3.3.5.2. Product Strategy 21.3.3.5.3. Channel Strategy 21.3.4. Sanofi S.A. 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.4.5.1. Marketing Strategy 21.3.4.5.2. Product Strategy 21.3.4.5.3. Channel Strategy 21.3.5. Novartis AG, 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.5.5.1. Marketing Strategy 21.3.5.5.2. Product Strategy 21.3.5.5.3. Channel Strategy 21.3.6. Bristol-Myers Squibb, 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.6.5.1. Marketing Strategy 21.3.6.5.2. Product Strategy 21.3.6.5.3. Channel Strategy 21.3.7. Boehringer Ingelheim GmbH 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.7.5.1. Marketing Strategy 21.3.7.5.2. Product Strategy 21.3.7.5.3. Channel Strategy 21.3.8. GlaxoSmithKline PLC 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.8.5.1. Marketing Strategy 21.3.8.5.2. Product Strategy 21.3.8.5.3. Channel Strategy 21.3.9. GILEAD Science Inc. 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.9.5.1. Marketing Strategy 21.3.9.5.2. Product Strategy 21.3.9.5.3. Channel Strategy 21.3.10. Albany Molecular Research Inc. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.10.5.1. Marketing Strategy 21.3.10.5.2. Product Strategy 21.3.10.5.3. Channel Strategy 21.3.11. AstraZeneca 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Profitability by Market Segments (Product/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Strategy Overview 21.3.11.5.1. Marketing Strategy 21.3.11.5.2. Product Strategy 21.3.11.5.3. Channel Strategy 21.3.12. Merck & Co, Inc. 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Profitability by Market Segments (Product/Channel/Region) 21.3.12.4. Sales Footprint 21.3.12.5. Strategy Overview 21.3.12.5.1. Marketing Strategy 21.3.12.5.2. Product Strategy 21.3.12.5.3. Channel Strategy 21.3.13. BASF SE 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Profitability by Market Segments (Product/Channel/Region) 21.3.13.4. Sales Footprint 21.3.13.5. Strategy Overview 21.3.13.5.1. Marketing Strategy 21.3.13.5.2. Product Strategy 21.3.13.5.3. Channel Strategy 21.3.14. Teva Pharmaceuticals 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Profitability by Market Segments (Product/Channel/Region) 21.3.14.4. Sales Footprint 21.3.14.5. Strategy Overview 21.3.14.5.1. Marketing Strategy 21.3.14.5.2. Product Strategy 21.3.14.5.3. Channel Strategy 21.3.15. Hoffmann-La Roche Ltd 21.3.15.1. Overview 21.3.15.2. Product Portfolio 21.3.15.3. Profitability by Market Segments (Product/Channel/Region) 21.3.15.4. Sales Footprint 21.3.15.5. Strategy Overview 21.3.15.5.1. Marketing Strategy 21.3.15.5.2. Product Strategy 21.3.15.5.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 02: Global Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 03: Global Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 04: Global Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 05: Global Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Region Table 06: North America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 07: North America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 08: North America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 09: North America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 10: North America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country Table 11: Latin America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 12: Latin America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 13: Latin America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 14: Latin America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 15: Latin America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country Table 16: Europe America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 17: Europe America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 18: Europe America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 19: Europe America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 20: Europe America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country Table 21: South Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 22: South Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 23: South Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 24: South Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 25: South Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country Table 26: East Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 27: East Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 28: East Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 28: MEA America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 29: East Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 30: East Asia America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country Table 31: Oceania America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 32: Oceania America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 33: Oceania America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application Table 34: Oceania America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 35: Oceania America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country Table 36: MEA America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Molecule Table 37: MEA America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Production Table 39: MEA America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Area Table 40: MEA America Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Small molecule Treatment Market Historical Market Value and Y-o-Y, 2017-2021 Figure 02: Global Small molecule Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 03: Global Small molecule Treatment Market Absolute $ Opportunity, 2022-2032 Figure 04: Global Small Molecules Market Historical Market Value (US$ Mn) Analysis, 2017-2021 Figure 05: Global Small Molecules Current and Future Market Value (US$ Mn), 2022-2032 & Y-o-Y Growth Trend Figure 06: Global Small Molecules Market Share Analysis (%) By Molecule, 2022 & 2032 Figure 07: Global Small Molecules Market Y-o-Y Growth (%) By Molecule, 2022-2032 Figure 08: Global Small Molecules Market Attractiveness Analysis, By Molecule Figure 09: Global Small Molecules Market Share Analysis (%) By Production, 2022 & 2032 Figure 10: Global Small Molecules Market Y-o-Y Growth (%) By Production, 2022-2032 Figure 11: Global Small Molecules Market Attractiveness Analysis, By Molecule Figure 12: Global Small Molecules Market Share Analysis (%) By Application, 2022 & 2032 Figure 13: Global Small Molecules Market Y-o-Y Growth (%) By Application, 2022-2032 Figure 14: Global Small Molecules Market Attractiveness Analysis, By Application Figure 15: Global Small Molecules Market Share Analysis (%) By Therapeutic Area, 2022 & 2032 Figure 16: Global Small Molecules Market Y-o-Y Growth (%) By Therapeutic Area, 2022-2032 Figure 17: Global Small Molecules Market Attractiveness Analysis, By Therapeutic Area Figure 18: Global Small Molecules Market Share Analysis (%) By Region, 2022 & 2032 Figure 19: Global Small Molecules Market Y-o-Y Growth (%) By Region, 2022-2032 Figure 20: Global Small Molecules Market Attractiveness Analysis, By Region Figure 21: North America Market Share, By Country (2022) Figure 22: North America Market Share, By Molecule (2022) Figure 23: North America Market Share, By Production (2022) Figure 24: North America Market Share, By Application (2022) Figure 25: North America Market Share, By Therapeutic Area (2022) Figure 26: North America Small Molecules Market Value (US$ Mn) Analysis, 2017-2021 Figure 27: North America Small Molecules Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 28: North America Small Molecules Market Attractiveness Analysis, By Molecule Figure 29: North America Small Molecules Market Attractiveness Analysis, By Production Figure 30: North America Small Molecules Market Attractiveness Analysis, By Application Figure 31: North America Small Molecules Market Attractiveness Analysis, By Country Figure 32: North America Small Molecules Market Attractiveness Analysis, By Production Figure 33: Latin America Market Share, By Country (2022) Figure 34: Latin America Market Share, By Molecule (2022) Figure 35: Latin America Market Share, By Production (2022) Figure 36: Latin America Market Share, By Application (2022) Figure 37: Latin America Market Share, By Therapeutic Area (2022) Figure 38: Latin America Small Molecules Market Value (US$ Mn) Analysis, 2017-2021 Figure 39: Latin America Small Molecules Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 40: Latin America Small Molecules Market Attractiveness Analysis, By Molecule Figure 41: Latin America Small Molecules Market Attractiveness Analysis, By Production Figure 42: Latin America Small Molecules Market Attractiveness Analysis, By Application Figure 43: Latin America Small Molecules Market Attractiveness Analysis, By Country Figure 44: Latin America Small Molecules Market Attractiveness Analysis, By Therapeutic area Figure 45: Europe America Market Share, By Country (2022) Figure 46: Europe America Market Share, By Molecule (2022) Figure 47: Europe America Market Share, By Production (2022) Figure 48: Europe America Market Share, By Application (2022) Figure 49: Europe America Market Share, By Therapeutic Area (2022) Figure 50: Europe Small Molecules Market Value (US$ Mn) Analysis, 2017-2021 Figure 51: Europe Small Molecules Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 52: Europe America Small Molecules Market Attractiveness Analysis, By Molecule Figure 53: Europe America Small Molecules Market Attractiveness Analysis, By Production Figure 54: Europe America Small Molecules Market Attractiveness Analysis, By Application Figure 55: Europe America Small Molecules Market Attractiveness Analysis, By Country Figure 56: Europe America Small Molecules Market Attractiveness Analysis, By Therapeutic area Figure 57: South Asia America Market Share, By Country (2022) Figure 58: South Asia America Market Share, By Molecule (2022) Figure 59: South Asia America Market Share, By Production (2022) Figure 60: South Asia America Market Share, By Application (2022) Figure 61: South Asia America Market Share, By Therapeutic Area (2022) Figure 62: South Asia Small Molecules Market Value (US$ Mn) Analysis, 2017-2021 Figure 63: South Asia Small Molecules Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 64: South Asia America Small Molecules Market Attractiveness Analysis, By Molecule Figure 65: South Asia America Small Molecules Market Attractiveness Analysis, By Production Figure 66: South Asia America Small Molecules Market Attractiveness Analysis, By Application Figure 67: South Asia America Small Molecules Market Attractiveness Analysis, By Country Figure 68: South Asia America Small Molecules Market Attractiveness Analysis, By Therapeutic area Figure 69: East Asia America Market Share, By Country (2022) Figure 70: East Asia America Market Share, By Molecule (2022) Figure 71: East Asia America Market Share, By Production (2022) Figure 72: East Asia America Market Share, By Application (2022) Figure 73: East Asia America Market Share, By Therapeutic Area (2022) Figure 74: East Asia Small Molecules Market Value (US$ Mn) Analysis, 2017-2021 Figure 75: East Asia Small Molecules Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 76: East Asia America Small Molecules Market Attractiveness Analysis, By Molecule Figure 77: East Asia America Small Molecules Market Attractiveness Analysis, By Production Figure 78: East Asia America Small Molecules Market Attractiveness Analysis, By Application Figure 79: East Asia America Small Molecules Market Attractiveness Analysis, By Country Figure 80: East Asia America Small Molecules Market Attractiveness Analysis, By Therapeutic area Figure 81: Oceania America Market Share, By Country (2022) Figure 82: Oceania America Market Share, By Molecule (2022) Figure 83: Oceania America Market Share, By Production (2022) Figure 84: Oceania America Market Share, By Application (2022) Figure 85: Oceania America Market Share, By Therapeutic Area (2022) Figure 86: Oceania Small Molecules Market Value (US$ Mn) Analysis, 2017-2021 Figure 87: Oceania Small Molecules Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 88: Oceania America Small Molecules Market Attractiveness Analysis, By Molecule Figure 89: Oceania America Small Molecules Market Attractiveness Analysis, By Production Figure 90: Oceania America Small Molecules Market Attractiveness Analysis, By Application Figure 91: Oceania America Small Molecules Market Attractiveness Analysis, By Country Figure 92: Oceania America Small Molecules Market Attractiveness Analysis, By Therapeutic area Figure 93: MEA America Market Share, By Country (2022) Figure 94: MEA America Market Share, By Molecule (2022) Figure 95: MEA America Market Share, By Production (2022) Figure 96: MEA America Market Share, By Application (2022) Figure 97: MEA America Market Share, By Therapeutic Area (2022) Figure 98: MEA Small Molecules Market Value (US$ Mn) Analysis, 2017-2021 Figure 99: MEA Small Molecules Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032 Figure 100: MEA America Small Molecules Market Attractiveness Analysis, By Molecule Figure 101: MEA America Small Molecules Market Attractiveness Analysis, By Production Figure 102: MEA America Small Molecules Market Attractiveness Analysis, By Application Figure 103: MEA America Small Molecules Market Attractiveness Analysis, By Country Figure 104: MEA America Small Molecules Market Attractiveness Analysis, By Therapeutic area Figure 105: U.S. Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 106: U.S. Market Share Analysis (%), by Production, 2022 & 2032 Figure 107: U.S. Market Share Analysis (%), by Application, 2022 & 2032 Figure 108: U.S. Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 109: U.S. Market Value Analysis (US$ Mn), 2022 & 2032 Figure 110: Canada Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 111: Canada Market Share Analysis (%), by Production, 2022 & 2032 Figure 112: Canada Market Share Analysis (%), by Application, 2022 & 2032 Figure 113: Canada Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 114: Canada Market Value Analysis (US$ Mn), 2022 & 2032 Figure 115: Brazil Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 116: Brazil Market Share Analysis (%), by Production, 2022 & 2032 Figure 117: Brazil Market Share Analysis (%), by Application, 2022 & 2032 Figure 118: Brazil Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 119: Brazil Market Value Analysis (US$ Mn), 2022 & 2032 Figure 120: Mexico Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 121: Mexico Market Share Analysis (%), by Production, 2022 & 2032 Figure 122: Mexico Market Share Analysis (%), by Application, 2022 & 2032 Figure 123: Mexico Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 124: Mexico Market Value Analysis (US$ Mn), 2022 & 2032 Figure 125: Argentina Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 126: Argentina Market Share Analysis (%), by Production, 2022 & 2032 Figure 127: Argentina Market Share Analysis (%), by Application, 2022 & 2032 Figure 128: Argentina Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 129: Argentina Market Value Analysis (US$ Mn), 2022 & 2032 Figure 130: Germany Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 131: Germany Market Share Analysis (%), by Production, 2022 & 2032 Figure 132: Germany Market Share Analysis (%), by Application, 2022 & 2032 Figure 133: Germany Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 134: Germany Market Value Analysis (US$ Mn), 2022 & 2032 Figure 135: U.K Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 136: U.K Market Share Analysis (%), by Production, 2022 & 2032 Figure 137: U.K Market Share Analysis (%), by Application, 2022 & 2032 Figure 138: U.K Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 139: U.K Market Value Analysis (US$ Mn), 2022 & 2032 Figure 140: France Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 141: France Market Share Analysis (%), by Production, 2022 & 2032 Figure 142: France Market Share Analysis (%), by Application, 2022 & 2032 Figure 143: France Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 144: France Market Value Analysis (US$ Mn), 2022 & 2032 Figure 145: Italy Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 146: Italy Market Share Analysis (%), by Production, 2022 & 2032 Figure 147: Italy Market Share Analysis (%), by Application, 2022 & 2032 Figure 148: Italy Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 149: Italy Market Value Analysis (US$ Mn), 2022 & 2032 Figure 150: Nordic Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 151: Nordic Market Share Analysis (%), by Production, 2022 & 2032 Figure 152: Nordic Market Share Analysis (%), by Application, 2022 & 2032 Figure 153: Nordic Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 154: Nordic Market Value Analysis (US$ Mn), 2022 & 2032 Figure 155: Benelux Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 156: Benelux Market Share Analysis (%), by Production, 2022 & 2032 Figure 157: Benelux Market Share Analysis (%), by Application, 2022 & 2032 Figure 158: Benelux Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 159: Benelux Market Value Analysis (US$ Mn), 2022 & 2032 Figure 160: Spain Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 161: Spain Market Share Analysis (%), by Production, 2022 & 2032 Figure 162: Spain Market Share Analysis (%), by Application, 2022 & 2032 Figure 163: Spain Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 164: Spain Market Value Analysis (US$ Mn), 2022 & 2032 Figure 165: Poland Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 166: Poland Market Share Analysis (%), by Production, 2022 & 2032 Figure 167: Poland Market Share Analysis (%), by Application, 2022 & 2032 Figure 168: Poland Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 169: Poland Market Value Analysis (US$ Mn), 2022 & 2032 Figure 170: Russia Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 171: Russia Market Share Analysis (%), by Production, 2022 & 2032 Figure 172: Russia Market Share Analysis (%), by Application, 2022 & 2032 Figure 173: Russia Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 174: Russia Market Value Analysis (US$ Mn), 2022 & 2032 Figure 175: China Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 176: China Market Share Analysis (%), by Production, 2022 & 2032 Figure 177: China Market Share Analysis (%), by Application, 2022 & 2032 Figure 178: China Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 179: China Market Value Analysis (US$ Mn), 2022 & 2032 Figure 180: Japan Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 181: Japan Market Share Analysis (%), by Production, 2022 & 2032 Figure 182: Japan Market Share Analysis (%), by Application, 2022 & 2032 Figure 183: Japan Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 184: Japan Market Value Analysis (US$ Mn), 2022 & 2032 Figure 185: South Korea Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 186: South Korea Market Share Analysis (%), by Production, 2022 & 2032 Figure 187: South Korea Market Share Analysis (%), by Application, 2022 & 2032 Figure 188: South Korea Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 189: South Korea Market Value Analysis (US$ Mn), 2022 & 2032 Figure 190: India Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 191: India Market Share Analysis (%), by Production, 2022 & 2032 Figure 192: India Market Share Analysis (%), by Application, 2022 & 2032 Figure 193: India Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 194: India Market Value Analysis (US$ Mn), 2022 & 2032 Figure 195: Thailand Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 196: Thailand Market Share Analysis (%), by Production, 2022 & 2032 Figure 197: Thailand Market Share Analysis (%), by Application, 2022 & 2032 Figure 198: Thailand Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 199: Thailand Market Value Analysis (US$ Mn), 2022 & 2032 Figure 200: Malaysia Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 201: Malaysia Market Share Analysis (%), by Production, 2022 & 2032 Figure 202: Malaysia Market Share Analysis (%), by Application, 2022 & 2032 Figure 203: Malaysia Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 204: Malaysian Market Value Analysis (US$ Mn), 2022 & 2032 Figure 205: Indonesia Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 206: Indonesia Market Share Analysis (%), by Production, 2022 & 2032 Figure 207: Indonesia Market Share Analysis (%), by Application, 2022 & 2032 Figure 208: Indonesia Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 209: Indonesia Market Value Analysis (US$ Mn), 2022 & 2032 Figure 210: Australia Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 211: Australia Market Share Analysis (%), by Production, 2022 & 2032 Figure 212: Australia Market Share Analysis (%), by Application, 2022 & 2032 Figure 213: Australia Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 214: Australia Market Value Analysis (US$ Mn), 2022 & 2032 Figure 215: New Zealand Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 216: New Zealand Market Share Analysis (%), by Production, 2022 & 2032 Figure 217: New Zealand Market Share Analysis (%), by Application, 2022 & 2032 Figure 218: New Zealand Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 219: New Zealand Market Value Analysis (US$ Mn), 2022 & 2032 Figure 220: GCC Countries Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 221: GCC Countries Market Share Analysis (%), by Production, 2022 & 2032 Figure 222: GCC Countries Market Share Analysis (%), by Application, 2022 & 2032 Figure 223: GCC Countries Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 224: GCC Countries Market Value Analysis (US$ Mn), 2022 & 2032 Figure 225: South Africa Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 226: South Africa Market Share Analysis (%), by Production, 2022 & 2032 Figure 227: South Africa Market Share Analysis (%), by Application, 2022 & 2032 Figure 228: South Africa Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 229: South Africa Market Value Analysis (US$ Mn), 2022 & 2032 Figure 230: North Africa Market Share Analysis (%), by Molecule, 2022 & 2032 Figure 231: North Africa Market Share Analysis (%), by Production, 2022 & 2032 Figure 232: North Africa Market Share Analysis (%), by Application, 2022 & 2032 Figure 233: North Africa Market Share Analysis (%), by Therapeutic Area, 2022 & 2032 Figure 234: North Africa Market Value Analysis (US$ Mn), 2022 & 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
